Guardant Health Inc

GH

101.850USD

+3.490+3.55%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking

47 / 205

Overall Ranking

137 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Guardant Health Inc Highlights

StrengthsRisks

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 64.39% year-on-year.

Undervalued

The company’s latest PE is -31.70, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 125.58M shares, decreasing 11.91% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 4.01K shares of this stock.

Analyst Rating

Based on 24 analysts

Buy

Current Rating

121.520

Target Price

+23.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Guardant Health Inc is 7.13, ranking 101 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 265.20M, representing a year-over-year increase of 38.50%, while its net profit experienced a year-over-year increase of 13.95%.

Score

Industry at a Glance

Previous score

7.13

Change

0



Financials

6.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.22

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.01

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.22

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Guardant Health Inc is 7.26, ranking 102 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -31.70, which is -100.00% below the recent high of 0.00 and -15.15% above the recent low of -36.50.

Score

Industry at a Glance

Previous score

7.26

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Guardant Health Inc is 8.58, ranking 21 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 100.00, with a high of 130.00 and a low of 48.21.

Score

Industry at a Glance

Previous score

8.58

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Guardant Health Inc is 6.97, ranking 63 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 115.89 and the support level at 92.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Guardant Health Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.47%, representing a quarter-over-quarter decrease of 2.60%. The largest institutional shareholder is The Vanguard, holding a total of 12.13M shares, representing 9.42% of shares outstanding, with 3.20% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.88M

-2.14%

BlackRock Institutional Trust Company, N.A.

8.57M

+2.09%

Baillie Gifford & Co.

Star Investors

5.13M

+6.61%

Capital International Investors

4.69M

-5.77%

Invesco Advisers, Inc.

4.64M

+36.43%

Deep Track Capital LP

4.15M

-2.26%

T. Rowe Price Associates, Inc.

Star Investors

4.10M

+148.51%

Two Sigma Investments, LP

3.92M

-7.56%

Eventide Asset Management, LLC

3.32M

-3.98%

Wellington Management Company, LLP

3.25M

+68.96%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Guardant Health Inc is 5.67, ranking 76 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.67. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Guardant Health Inc

GH

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment